Johnson & Johnson (NYSE:JNJ) Shares Bought by Signet Investment Advisory Group Inc.

Posted by Defense World Staff on Apr 1st, 2023

Signet Investment Advisory Group Inc. lifted its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,025 shares of the company’s stock after purchasing an additional 583 shares during the period. Johnson & Johnson accounts for approximately 3.0% of Signet Investment Advisory Group Inc.’s investment portfolio, making the stock its 8th biggest holding. Signet Investment Advisory Group Inc.’s holdings in Johnson & Johnson were worth $4,244,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in JNJ. Vanguard Group Inc. boosted its holdings in shares of Johnson & Johnson by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after acquiring an additional 2,815,655 shares in the last quarter. State Street Corp boosted its holdings in shares of Johnson & Johnson by 0.6% during the 3rd quarter. State Street Corp now owns 141,886,311 shares of the company’s stock valued at $23,178,548,000 after acquiring an additional 803,013 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Johnson & Johnson by 3.3% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock valued at $4,154,022,000 after acquiring an additional 805,831 shares in the last quarter. Legal & General Group Plc lifted its holdings in Johnson & Johnson by 2.3% during the 2nd quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock worth $3,344,295,000 after buying an additional 421,779 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Johnson & Johnson by 1.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after buying an additional 328,297 shares during the period. Institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $155.00 on Friday. The firm has a market cap of $403.66 billion, a P/E ratio of 23.00, a PEG ratio of 2.64 and a beta of 0.54. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. The company has a 50 day moving average of $158.02 and a 200 day moving average of $167.12. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.22 by $0.13. The firm had revenue of $23.71 billion during the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. Johnson & Johnson’s revenue was down 4.4% on a year-over-year basis. During the same period in the prior year, the business posted $2.13 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.92%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 67.06%.

Insider Buying and Selling at Johnson & Johnson

In other news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on JNJ shares. Guggenheim started coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective on the stock. Morgan Stanley boosted their target price on Johnson & Johnson from $176.00 to $180.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 25th. StockNews.com assumed coverage on Johnson & Johnson in a research report on Thursday, March 16th. They issued a “strong-buy” rating for the company. Citigroup boosted their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a report on Monday, December 12th. Finally, UBS Group assumed coverage on Johnson & Johnson in a report on Tuesday. They issued a “neutral” rating and a $164.00 target price for the company. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $173.67.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.